Osteotech recommences tissue processing:
This article was originally published in Clinica
Osteotech restarted base tissue segment processing at its Shrewsbury, New Jersey facility on October 9 as planned (see Clinica No 1028, p 16). It says it is also on target to recommence processing at its Eatontown site in late October. Donor processing volumes are expected to take nine weeks to return to normal levels because of additional control procedures implemented following the FDA's inspection. Osteotech's third-quarter revenues will be reduced by $1.3m and net income per share by about 2 cents as a result of the temporary stoppage.